Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK, Sung JH, Ha SJ, Kim HR, Chang H, Kim JH, Tania C, Cho BC. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2012 Dec 19 doi: 10.1016/j.lungcan.2012.11.017. [Epub ahead of print]
Kim SH, Shin SJ, Kim SY, Lee SH, Park YS, Park SH, Lee KH, Kim TW, Hong YS, Ahn JB. Combining capecitabine, oxaliplatin and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial Cancer Chemother Pharmacol. 2012;69(1):91-7.
Kim SH, Cho BC, Choi HJ, Chung KY, Kim DJ, Park MS, Kim SK, Chang J, Shin SJ, Sohn JH, Kim JH. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. Lung Cancer 2008;60(3):393-400.
Kim SH, Chung HC, Jeong J, Kim JH, Rha SY, Ahn JB, Cho NH, Jeung HC. A locally advanced breast cancer with difficult differential diagnosis of carcinosarcoma and atypical medullary carcinoma, which had poor response to adriamycin- and taxane-based neoadjuvant chemotherapy: a case report. Cancer Res Treat 2007;39(3):134-7.
Chang H, Kim SH, Cho BC, Yoon SH, Kim HR, Lee CG, Kim JH. Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. Anticancer Res 2012; 32: 3515-3522
Jeong J, Cho BC, Sohn JH, Choi HJ, Kim SH, Lee YJ, Jung MK, Shin SJ, Park MS, Kim SK, Chang J, Kim JH. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer 2010 Oct;70(1):77-81
Choi HJ, Cho BC, Sohn JH, Shin SJ, Kim SH, Kim JH, Yoo NC. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome. J Neurooncol. 2009 Feb;91(3):307-13.
Choi H, Kim SH, Moon JH, Lee YH, Rhee Y, Kang ES, Ahn CW, Cha BS, Lee EJ, Kim KR, Lee HC, Jeong SY, Kim HJ, Lim SK. Multiple endocrine neoplasia type 1 with multiple leiomyomas linked to a novel mutation in the MEN1 gene. Yonsei Med J 2008;49(4):655-61.
Shin SJ, Lee HW, Kim SH, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Pyo JY, Roh JK. Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. Acta Oncol 2007;46(4):547-9.